Pharmaceutical composition for treating diabetes, comprising pancreatic islet cells and elastin-like artificial extracellular matrix
View Patent ↗The present invention relates to a pharmaceutical composition for treating diabetes, which includes a pancreatic islet cell and an elastin-like artificial extracellular matrix (REP), and more particularly, to a pharmaceutical composition for treating diabetes, in which pancreatic islet cells are reacted with an elastin-like artificial extracellular matrix and then the resulting cells are administered along with the elastin-like artificial extracellular matrix, thus increasing a survival rate of the transplanted pancreatic islet cells, rapidly restoring a blood glucose level to normal, and maintaining the restored blood glucose level for a long period of time, and, accordingly, diabetes may be more effectively treated.
1. A method for treating diabetes, the method comprising administering to an individual having diabetes a pharmaceutical composition comprising:
a pancreatic islet cell; and
an elastin-like artificial extracellular matrix (REP) prepared through repeated fusion of an elastin-like polypeptide and a ligand,
wherein the elastin-like artificial extracellular matrix is [VGRGD(VGVPG) 6 ] n where n=10, 12, 15, or 20 (SEQ ID NO: 4), and
wherein the pancreatic islet cell is a cell which was reacted with a solution of [VGRGD(VGVPG) 6 ] n where n=10, 12, 15, or 20 (SEQ ID NO: 4).
2. The method of claim 1 , wherein the pancreatic islet cell is isolated from any one individual selected from the group consisting of a human, a mouse, a rat, a pig, a rabbit, a guinea pig, a hamster, a dog, a cat, a cow, and a goat.
3. The method of claim 1 , wherein the pharmaceutical composition comprises: 800 to 2,000 pancreatic islet cells; and 0.5 μM to 10 μM of an elastin-like artificial extracellular matrix.
4. The method of claim 1 , wherein the individual has type 1 diabetes.